- NIH Distinguished Investigator, Lymphoid Malignancies Branch
Dr. Waldmann received his M.D. from Harvard Medical School. He joined the NCI in 1956 and has been chief of the Lymphoid Malignancies Branch(Metabolism Branch) since 1973. He studies the IL-2/IL-2 receptor system in the growth of normal and neoplastic cells. He co-discovered IL-15 and introduced rhIL-15, IL-2/IL-15R (CD122), Hu-Mik-Beta-1-directed therapy for cancer and autoimmune diseases. He has initiated clinical trials employing IL-15 in the treatment of metastatic malignancy. His honors include the Ehrlich medal; the Stratton, Lila Gruber, Simon Shubitz, Milken, Artois-Baillet Latour, and Bristol-Myers Squibb prizes; AAI-Dana Foundation Award in Human Immunology Research; and election to the National Academy of Sciences, American Academy of Arts and Sciences, Institute of Medicine, NAS and the Royal Society of the Medical Sciences UK.
- (2020). Y-90-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 35(4), 249-261.
- (2019). Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 145(6), 1437-1448.
- (2019). Cytokines in the Treatment of Cancer. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 39(1), 6-21.
- (2019). First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances. 3(13), 1970-1980.
- (2019). IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective gamma-chain cytokines, decreases leukemic T-cell viability. LEUKEMIA. 33(5), 1243-1255.